What is Pharming Group N.V. (PHAR)'s fair-value range?

As of 2026-10-23, Pharming Group N.V. (PHAR) trades at $10.67 — Cboe · delayed 15 min · as of 20:04 ET. That price implies EV/EBITDA 41.2×, FCF yield 8.9%. Whether those assumptions are reasonable is your call: every method on the page shows the number today's price implies for its key input — the P/E, the growth rate, the multiple — and you set your own, from a 1, 3, 5 or 10-year filed CAGR or a rate of your choosing. With EvidInvest's preset inputs the 4 methods land at $1.70–$7.38; presets are filed history and reference settings, not a recommendation. Not investment advice.

How is Pharming Group N.V. (PHAR)'s fair value calculated?

Pharming Group N.V. (PHAR)'s fair value is computed with several independent methods — a discounted cash flow (DCF) model, the Graham number, earnings power value (EPV), and valuation multiples such as PE and EV/EBITDA — using data from SEC filings. P/B is optional for non-financial companies and included in the preset range for financial sectors.

What is Pharming Group N.V. (PHAR)'s PE ratio versus its industry?

EvidInvest shows Pharming Group N.V. (PHAR)'s current and historical PE ratio alongside its sector and industry averages, so you can see whether the stock trades at a premium or discount to peers. Full breakdown at https://evidinvest.com/valuation/PHAR.

Fair value · Pharming Group N.V. (PHAR) · updated 2026-10-23 · from 20-F FY2025

Pharming Group trades at $10.67. That price implies 41.2× EV/EBITDA and a 8.9% free-cash-flow yield.

Cboe · delayed 15 min · as of 20:04 ET

Per-share figures are stated per ADS (10 ordinary shares per ADS) to match the quoted price.

Are those assumptions reasonable? Use PHAR’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.

What the price implies

EV/EBITDA: 41.2×
FCF yield: 8.9%

Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 20:04 ET.

With preset inputs the methods land at $1.70 – $7.38 (presets are filed history and our reference settings, not a recommendation)

Price $10.67

Bear $1.70Base $3.04Bull $7.38

Set your own assumptions ↓See how each method got its number Check another stock

How each method got its number

Bear, base and bull are the 25th, 50th and 75th percentile of the methods that produced a usable estimate. Weights say how much a method is trusted for this sector; they do not change the range.

Method	Estimate	vs price	Weight	Why this method
DCF High weight Projects free cash flow for the coming years and discounts it back to today. The most complete method, and the most sensitive to the growth and discount-rate assumptions.	$0.54	-95%	High weight	Projects free cash flow for the coming years and discounts it back to today. The most complete method, and the most sensitive to the growth and discount-rate assumptions.
Earnings Power Value Medium weight Greenwald’s Earnings Power Value: what current earnings are worth if they never grow. Everything above it is what you pay for growth. Using normalized EBIT (3-year average)	$2.09	-80%	Medium weight	Greenwald’s Earnings Power Value: what current earnings are worth if they never grow. Everything above it is what you pay for growth.
EV/EBITDA Medium weight Values the whole business at 10× EBITDA and divides by the share count. A mid-cycle industrial multiple; fast growers trade far above it.	$3.99	-63%	Medium weight	Values the whole business at 10× EBITDA and divides by the share count. A mid-cycle industrial multiple; fast growers trade far above it.
EV/FCF Medium weight 20× free cash flow per share, i.e. a 5% cash yield. Reads low for companies the market expects to keep growing. Based on latest annual FCF (quarterly TTM unavailable)	$18	+64%	Medium weight	20× free cash flow per share, i.e. a 5% cash yield. Reads low for companies the market expects to keep growing.
P/E vs sector Medium weight Trailing diluted EPS times the sector median P/E. What the stock would be worth if the market priced it like an average peer. Negative or unavailable EPS	No estimate		Medium weight	Trailing diluted EPS times the sector median P/E. What the stock would be worth if the market priced it like an average peer.
Growth-trajectory DCF Medium weight A two-stage DCF that grows earnings at the company’s own EPS trend, then fades to the industry’s long-run rate. No trajectory data available	No estimate		Medium weight	A two-stage DCF that grows earnings at the company’s own EPS trend, then fades to the industry’s long-run rate.
P/B vs sector Medium weight Sector median price-to-book times book value per share. Works for banks and asset-heavy businesses, says little about software. P/B comparable is optional for non-financial companies	No estimate		Medium weight	Sector median price-to-book times book value per share. Works for banks and asset-heavy businesses, says little about software.
Graham Number Medium weight Benjamin Graham’s 1949 rule of thumb: √(22.5 × EPS × book value). It punishes asset-light companies, so it reads low for big tech. Requires positive EPS	No estimate		Medium weight	Benjamin Graham’s 1949 rule of thumb: √(22.5 × EPS × book value). It punishes asset-light companies, so it reads low for big tech.

What this means

A range of $1.70 to $7.38 means the methods disagree by more than 2×. They measure different things — cash the business earns today versus growth the market expects tomorrow — so treat the range as a rough guide, not a target.
The base case, $3.04, is the median of the 4 methods with data. It assumes Pharming Group’s current margins, cash generation and share count persist; it does not price in a new product cycle, a recession or a buyback surge.
The number moves when the filings move: the next quarterly statement replaces the oldest quarter in the trailing-twelve-month EPS and cash-flow inputs. The price changes every day; the fair value only changes with the filings.

The filing behind these numbers

Pharming Group N.V.

Revenue: $376.1M
Diluted EPS: $0.00
Free cash flow: $54.0M; operating cash flow − capital expenditure
Diluted shares: 746.9M; weighted average

20-F FY2025 · fiscal year ended 2025-12-31 · filed 2026-04-02 · accession 0001828316-26-000015

Open this filing on sec.gov

Valuation tool: build your own PHAR range

Fair Value Summary

Daily Price — PHAR

$10.67 -18.5% (1Y)

Range implied by today’s price3 of 7 methods

$11 – $11

Price $10.67

Bear $11Base $11Bull $11

Range with preset inputs

$1.70 – $7.38

Price $10.67

Bear $1.70Base $3.04Bull $7.38

Every method that could be solved backwards opens on the assumption today’s price makes, so the top range sits on the price — that is arithmetic, not a view. Change any input and it becomes yours.

We don’t tell you what PHAR is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has PHAR’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.

Discounted cash flow

N/A

Starting free cash flow is not positive; the model has nothing to grow.

Your stage-1 FCF growth (5.0%) is above the -24.0% the price implies.

Preset inputs — revenue-driven DCF from the latest filing

Two-stage FCF model at the same filed inputs: $41.88 — move any slider below and that model takes over.

• Starting free cash flow is not positive; the model has nothing to grow.

Implied by today’s price

At $10.67 the market implies a stage-1 FCF growth of -24.0%. (two-stage FCF model solved for stage-1 growth at 4.75% WACC)

The price implies stage-1 FCF growth of -24.0%, outside the range this slider covers. Showing preset inputs.

Implied discount rate (holding growth): 12.6% · the WACC that makes the same model print the price

That is the assumption the market is making — not ours, and not a recommendation. Decide whether it is reasonable: the growth matrix shows what PHAR has actually filed, and the AI chat will reason it through with you.

Your inputs

Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.

Stage-1 growth5.0%

Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.

-20.0%60.0%

Stage-1 years5 yrs

How long stage-1 growth lasts.

1 yrs10 yrs

Stage-2 growth2.5%

Slower growth after stage 1, before the terminal phase.

-20.0%30.0%

Stage-2 years5 yrs

0 yrs10 yrs

Terminal growth2.5%

Growth forever after the two stages. Above ~3% is rarely justified.

0.0%5.0%

Discount rate (WACC)4.75%

The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.

3.00%15.00%

Net debt ($M)Debt minus cash, from the balance sheet. Subtracted from enterprise value.

Starting FCF ($M)Latest free cash flow from the filing (operating cash flow minus capex).

Shares (M)Diluted shares, from the filing.

Year by year (two-stage model, $M)

PV explicit $528M · PV terminal $2,233M · EV $2,761M · equity $2,889M

Year	Stage	FCF	Present value
1	Stage 1	$57M	$54M
2	Stage 1	$60M	$54M
3	Stage 1	$63M	$54M
4	Stage 1	$66M	$55M
5	Stage 1	$69M	$55M
6	Stage 2	$71M	$53M
7	Stage 2	$72M	$52M
8	Stage 2	$74M	$51M
9	Stage 2	$76M	$50M
10	Stage 2	$78M	$49M

Inputs from the filing

Free cash flow: $54.0M; latest full year
EBIT: $25.8M; latest annual
Shares: 68.9M; ADS equivalent
Total debt: $17.7M
Cash: $145.3M
Net debt: $-127.6M; debt − cash

20-F FY2025 · period ended 2025-12-31 · filed 2026-04-02 · accession 0001828316-26-000015 · sec.gov

Prefer a blank slate with reverse DCF? Open the standalone DCF / reverse DCF for PHAR

Loading history...

Download the full PHAR valuation report (PDF) — free

DCF fair value, Graham number, EPV, key multiples and growth rates in one clean PDF.

Pharming Group trades at $10.67. That price implies 41.2× EV/EBITDA and a 8.9% free-cash-flow yield.

How each method got its number

What this means

The filing behind these numbers

Valuation tool: build your own PHAR range

Daily Price — PHAR

Range implied by today’s price3 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on PHAR

Compare with peers

Explore

Valuation tool: build your own PHAR range

Daily Price — PHAR

Range implied by today’s price3 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on PHAR

Compare with peers

Explore